Amylyx Pharmaceuticals, Inc. DEF 14A Filing

Ticker: AMLX · Form: DEF 14A · Filed: Apr 24, 2024 · CIK: 1658551

Sentiment: neutral

Topics: Amylyx Pharmaceuticals, AMLX, DEF 14A, Proxy Statement, Executive Compensation

TL;DR

<b>Amylyx Pharmaceuticals, Inc. files DEF 14A on April 24, 2024.</b>

AI Summary

Amylyx Pharmaceuticals, Inc. (AMLX) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Filing type is DEF 14A, filed on 2024-04-24. Company name is Amylyx Pharmaceuticals, Inc. SEC file number is 001-41199. Business address is 43 THORNDIKE STREET, CAMBRIDGE, MA 02141. Fiscal year ends on 12/31.

Why It Matters

For investors and stakeholders tracking Amylyx Pharmaceuticals, Inc., this filing contains several important signals. This filing is a Definitive Proxy Statement (DEF 14A), indicating it contains information for shareholders regarding upcoming meetings and voting matters. The filing provides details on executive compensation, equity awards, and other corporate governance information relevant to shareholders.

Risk Assessment

Risk Level: low — Amylyx Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosure information without immediate financial or operational news.

Analyst Insight

Review the executive compensation and equity award details to understand potential impacts on shareholder value and management incentives.

Key Numbers

Key Players & Entities

FAQ

When did Amylyx Pharmaceuticals, Inc. file this DEF 14A?

Amylyx Pharmaceuticals, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 24, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Amylyx Pharmaceuticals, Inc. (AMLX).

Where can I read the original DEF 14A filing from Amylyx Pharmaceuticals, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Amylyx Pharmaceuticals, Inc..

What are the key takeaways from Amylyx Pharmaceuticals, Inc.'s DEF 14A?

Amylyx Pharmaceuticals, Inc. filed this DEF 14A on April 24, 2024. Key takeaways: Filing type is DEF 14A, filed on 2024-04-24.. Company name is Amylyx Pharmaceuticals, Inc.. SEC file number is 001-41199..

Is Amylyx Pharmaceuticals, Inc. a risky investment based on this filing?

Based on this DEF 14A, Amylyx Pharmaceuticals, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosure information without immediate financial or operational news.

What should investors do after reading Amylyx Pharmaceuticals, Inc.'s DEF 14A?

Review the executive compensation and equity award details to understand potential impacts on shareholder value and management incentives. The overall sentiment from this filing is neutral.

How does Amylyx Pharmaceuticals, Inc. compare to its industry peers?

Amylyx Pharmaceuticals operates in the pharmaceutical preparations industry.

Are there regulatory concerns for Amylyx Pharmaceuticals, Inc.?

The filing is a DEF 14A, a standard SEC filing for public companies.

Industry Context

Amylyx Pharmaceuticals operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is a DEF 14A, a standard SEC filing for public companies.

What Investors Should Do

  1. Analyze executive compensation details for key personnel like Joshua Cohen and Justin Klee.
  2. Review equity award grants and changes in fair value for the fiscal years 2021, 2022, and 2023.
  3. Understand the corporate governance proposals being presented to shareholders.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure and does not represent a change from previous filings of the same type.

Filing Stats: 4,847 words · 19 min read · ~16 pages · Grade level 11.1 · Accepted 2024-04-24 07:07:51

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 22 COMPENSATION DISCUSSION AND ANALYSIS 22 REPORT OF THE COMPENSATION COMMITTEE 30 DIRECTOR COMPENSATION 48 DELINQUENT SECTION 16(a) REPORTS 50 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 51

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 53 REPORT OF THE AUDIT COMMITTEE 55 HOUSEHOLDING 56 STOCKHOLDER PROPOSALS 56 ANNUAL REPORT ON FORM 10-K 57 OTHER MATTERS 57 Table of Contents PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS This proxy statement contains information about the 2024 Annual Meeting of Amylyx Pharmaceuticals, Inc., which will be held online on June 6, 2024, at 9:00 a.m. Eastern Time. The Annual Meeting will be a virtual meeting, which will be conducted via live webcast. You may attend and participate in the meeting virtually by visiting https://meetnow.global/MHTTH5N, where you will be able to vote electronically and submit questions prior to and during the meeting. The board of directors of Amylyx Pharmaceuticals, Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms "Amylyx Pharmaceuticals," "Amylyx," the "Company," "we," "us," and "our" refer to Amylyx Pharmaceuticals, Inc. The mailing address of our principal executive offices is Amylyx Pharmaceuticals, Inc., 43 Thorndike St., Cambridge, MA 02141. Please see the "General Information" section of the proxy statement for more details regarding the logistics of the virtual Annual Meeting, including the ability of stockholders to submit questions during the Annual Meeting, and technical details and support related to accessing the virtual platform. There is no physical location for the Annual Meeting. You will not be able to attend the Annual Meeting in person. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is exercised at the meeting b

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing